GlassScriptPhysician profile
Amisha C Spille
NPI 1437561040
$1,110.20
in general payments reported to CMS, 2019-2025
15 companies · $397 in 2025
The $397 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.30 · 2022: $82.50 · 2023: $235 · 2024: $348 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.76 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.41 | 2021-2025 | Gattex |
| Daiichi Sankyo INC. | $65.20 | 2022-2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.27 | 2022-2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $59.80 | 2024-2025 | Iqirvo |
| Lilly USA, LLC | $45.20 | 2024 | Omvoh |
| Qol Medical, LLC | $30.83 | 2022-2023 | Sucraid |
| Gilead Sciences, INC. | $23.05 | 2024 | |
| Organon LLC | $22.97 | 2025 | Hadlima |
| Orphalan INC | $22.29 | 2025 | Cuvrior |
| Mallinckrodt Hospital Products INC. | $20.37 | 2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $19.72 | 2025 | Vowst |
| Ferring Pharmaceuticals INC. | $19.65 | 2022 | |
| Ardelyx, INC. | $18.12 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amisha Spille listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.